Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Bilastine→

Bilastine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
202189-78-4
Molecular formula
C28H37N3O3
Molecular weight
463.6 g/mol
Drug class
Second-generation, non-sedating selective peripheral H1-histamine receptor antagonist
Mechanism of action
Selectively antagonises peripheral histamine H1 receptors and has no meaningful affinity for muscarinic receptors at therapeutic concentrations.
Indications / reported uses
  • Symptomatic treatment of seasonal and perennial allergic rhinoconjunctivitis
  • Symptomatic treatment of urticaria; the cited UK 20 mg tablet authorisation is for adults and adolescents aged 12 years and over

Sources: UK SmPC — Bilastine 20 mg tablets · UK SmPC — Ilaxten 20 mg tablets · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Bilastine Environmental Risk Assessment (ERA) (the Bilastine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.